Absolute lymphocyte count at day + 21 predicts survival in patients with early-stage diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, adriamycin, vincristine and prednisone

References

• Coiffier B, Lepage E, Briere J . CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C . Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005;23:4117–4126.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Osterborg A . CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379–391.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Donaldson J, Chhanabhai M, . Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005;23:5027–5033.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Berry B, Chhanabhai M, . The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857–1861.
   PubMed Web of Science ®Google Scholar
• Chae YS, Kim JG, Sohn SK . Lymphotoxin alfa and receptor-interacting protein kinase 1 gene polymorphisms may correlate with prognosis in patients with diffuse large B cell lymphoma treated with R-CHOP. Cancer Chemother Pharmacol 2010;65:571–577.
   PubMed Web of Science ®Google Scholar
• Barrans S, Crouch S, Smith A, . Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 2010;28: 3360–3365.
   PubMed Web of Science ®Google Scholar
• Yoon DH, Choi DR, Ahn HJ, . Ki-67 expression as a prognostic factor in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP. Eur J Haematol 2010;85:149–157.
   PubMed Web of Science ®Google Scholar
• Talaulikar D, Choudhury A, Shadbolt B, . Lymphocytopenia as a prognostic marker for diffuse large B cell lymphomas. Leuk Lymphoma 2008;49:959–964.
   PubMed Web of Science ®Google Scholar
• Cox MC, Nofroni I, Ruco L . Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma. Leuk Lymphoma 2008;49:1745–1751.
   PubMed Web of Science ®Google Scholar
• Oki Y, Yamamoto K, Kato H, . Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients’ survival benefit from rituximab. Eur J Haematol 2008;81:448–453.
   PubMed Web of Science ®Google Scholar
• Song MK, Chung JS, Seol YM, . Influence of low absolute lymphocyte count of patients with nongerminal center type diffuse large B-cell lymphoma with R-CHOP therapy. Ann Oncol 2010;21: 140–144.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, . Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Zhou T, Jiang Y, Yao J. [Expression of adhesion molecules on lymphocyte in patients with systemic lupus erythematosus]. Zhonghua Nei Ke Za Zhi 1995;34:545–547.
   PubMedGoogle Scholar
• Kim H, Sohn HJ, Kim SE, . Lymphocyte recovery as a positive predictor of prolonged survival after autologous peripheral blood stem cell transplantation in T-cell non-Hodgkin's lymphoma. Bone Marrow Transplant 2004;34:43–49.
   PubMed Web of Science ®Google Scholar
• Kim H, Sohn HJ, Kim S, . Early lymphocyte recovery predicts longer survival after autologous peripheral blood stem cell transplantation in multiple myeloma. Bone Marrow Transplant 2006;37:1037–1042.
   PubMed Web of Science ®Google Scholar
• Joao C, Porrata LF, Inwards DJ, . Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma. Bone Marrow Transplant 2006;37: 865–871.
   PubMed Web of Science ®Google Scholar
• Boulassel MR, Herr AL, deB Edwardes MD, . Early lymphocyte recovery following autologous peripheral stem cell transplantation is associated with better survival in younger patients with lymphoproliferative disorders. Hematology 2006;11: 165–170.
   PubMed Web of Science ®Google Scholar
• Behl D, Porrata LF, Markovic SN, . Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia 2006;20:29–34.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Inwards DJ, Ansell SM, . Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study. Biol Blood Marrow Transplant 2008;14:807–816.
   PubMed Web of Science ®Google Scholar
• Porrata LF, Ingle JN, Litzow MR, . Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Bone Marrow Transplant 2001;28:865–871.
   PubMed Web of Science ®Google Scholar
• Kim DH, Baek JH, Chae YS, . Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma. Leukemia 2007;21:2227–2230.
   PubMed Web of Science ®Google Scholar
• Paiva M, Marques H, Martins A, . FcgammaRIIa polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patients. Cancer Genet Cytogenet 2008;183:35–40.
   PubMed Web of Science ®Google Scholar
• Hatjiharissi E, Hansen M, Santos DD, . Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy. Clin Lymphoma Myeloma 2007;7:286–290.
   PubMedGoogle Scholar
• Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21: 3940–3947.
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G, . Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99:754–758.
   PubMed Web of Science ®Google Scholar
• Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 2001;40:205–211.
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez AJ, Link BK, . Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825–2833.
   PubMed Web of Science ®Google Scholar